within Pharmacolibrary.Drugs.ATC.C;

model C03AA01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 2.6666666666666667e-05,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.014,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005833333333333333,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C03AA01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Bendroflumethiazide is a thiazide diuretic approved for the management of hypertension and edema associated with congestive heart failure, liver cirrhosis, and renal disorders. It acts by inhibiting sodium reabsorption in the distal convoluted tubules of the kidney. It is approved and used in clinical practice today, often in low-dose combinations for hypertension.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects after oral administration.</p><h4>References</h4><ol><li><p>Borgström, L, et al., &amp; Lenander, R (1981). Pharmacokinetics of bendroflumethiazide after low oral doses. <i>Journal of pharmacokinetics and biopharmaceutics</i> 9(4) 431–441. DOI:<a href=&quot;https://doi.org/10.1007/BF01060887&quot;>10.1007/BF01060887</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7310642/&quot;>https://pubmed.ncbi.nlm.nih.gov/7310642</a></p></li><li><p>McAinsh, J, et al., &amp; Young, J (1981). Bioavailability of propranolol and bendrofluazide formulations. <i>Biopharmaceutics &amp; drug disposition</i> 2(2) 167–175. DOI:<a href=&quot;https://doi.org/10.1002/bdd.2510020209&quot;>10.1002/bdd.2510020209</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7248480/&quot;>https://pubmed.ncbi.nlm.nih.gov/7248480</a></p></li><li><p>Schäfer-Korting, M, et al., &amp; Mutschler, E (1982). Does cantharides blister fluid provide access to the peripheral compartment?. <i>European journal of clinical pharmacology</i> 23(4) 327–330. DOI:<a href=&quot;https://doi.org/10.1007/BF00613614&quot;>10.1007/BF00613614</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7173302/&quot;>https://pubmed.ncbi.nlm.nih.gov/7173302</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C03AA01;
